Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors.

Susan A KennedyMaria E MorrisseyMargaret R DunneFiona O'ConnellClare T ButlerMary-Clare CathcartAmy M BuckleyBrian J MehiganJohn O LarkinPaul McCormickBreandán N KennedyJacintha N O'Sullivan

Published in: BMC cancer (2020)

Our results indicate the anti-angiogenic small molecule 1,4-dihydroxy quininib could be an alternative novel treatment in combination therapy for CRC patients.

Keyphrases

small molecule
end stage renal disease
ejection fraction
chronic kidney disease
oxidative stress
peritoneal dialysis
metastatic colorectal cancer
patient reported outcomes